Search for a command to run...
Promoter shareholding in Bafna Pharmaceuticals decreased by 13.29% YoY and QoQ, contrasting with stable sector averages.
Institutional investment rose by 8.53%, suggesting smart money sees potential despite promoter selling, indicating a divergence from the broader sector trend.
Comparison with sector performers shows Bafna underperforming, with the worst performer in the sector (NECTAR LIFE) seeing a larger institutional decline of -15.93%.
| Category | Trend | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|
1Promoter10 | 88.74% | 88.43% | 88.3% | 88.3% | 88.3% | 88.3% | 75.01% | 75.01% | |
2Institution5 | - | - | - | - | - | - | 8.53% | 9.34% | |
3Public5 | 1.36% | 1.36% | 1.74% | 1.74% | 1.73% | 1.74% | 4.66% | 5% |